Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

8.27USD
25 May 2017
Change (% chg)

$-0.07 (-0.84%)
Prev Close
$8.34
Open
$8.41
Day's High
$8.43
Day's Low
$8.19
Volume
494,315
Avg. Vol
976,663
52-wk High
$13.38
52-wk Low
$3.11

Latest Key Developments (Source: Significant Developments)

Array BioPharma Q3 loss per share $0.21
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Array Biopharma Inc :Array biopharma reports financial results for the third quarter of fiscal 2017.Q3 loss per share $0.21.Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.Q3 revenue $33.3 million versus i/b/e/s view $37 million.Array biopharma inc - is on track to file an nda for columbus in june or july 2017.Array biopharma inc - revenue for q3 of fiscal 2017 was $33.3 million, compared to $44.5 million for prior sequential quarter.Array biopharma inc - cash, cash equivalents and marketable securities as of march 31, 2017 were $207 million.  Full Article

Array Biopharma announces positive top-line results from part 2 of the phase 3 columbus study of binimetinib and encorafenib
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Array Biopharma Inc :Array Biopharma announces positive top-line results from part 2 of the phase 3 Columbus study of binimetinib and encorafenib for braf-mutant melanoma.Array Biopharma Inc - new drug application filing on track for June or July 2017.Array - median PFS for patients on combination of binimetinib (45mg) plus encorafenib (300mg) 12.9 months versus 9.2 months for patients on encorafenib (300mg).Array Biopharma Inc- COMBO300 generally well-tolerated, reported dose intensity, adverse events were consistent with COMBO450 results in Columbus part 1.  Full Article

Array enters into loan, security agreement
Friday, 23 Dec 2016 04:24pm EST 

Array Biopharma Inc : Array Biopharma -on December 22, 2016 entered into loan and security agreement providing for term loan in original principal amount of $15 million . Array Biopharma -on December 22, 2016 entered into loan and security agreement providing for revolving line of credit of up to $5 million . Array Biopharma Inc - loan agreement also provides for revolving line of credit of up to $5 million - SEC filing .Array Biopharma -co requested issuance of letter of credit of $2.8 million to secure obligations under lease agreement for Boulder, Colorado facilities.  Full Article

Array Biopharma prices public offering at $6.25 per share
Tuesday, 27 Sep 2016 09:25pm EDT 

Array Biopharma Inc : Array Biopharma announces pricing of public offering of common stock .Says public offering of 18.4 million common shares priced at $6.25 per share.  Full Article

Array Biopharma announces proposed public offering of common stock
Tuesday, 27 Sep 2016 04:27pm EDT 

Array Biopharma Inc : Array Biopharma announces proposed public offering of common stock .Commenced an underwritten public offering of $100 million of shares of its common stock.  Full Article

Array Biopharma enters into note purchase agreement
Friday, 2 Sep 2016 05:15pm EDT 

Array Biopharma Inc : On Sept 2, co entered into note purchase agreement - SEC filing . Notes bear interest at rate of 5 percent per annum . Co issued to Redmile subordinated convertible promissory notes (in aggregate original principal amount of $10 million Source: (http://bit.ly/2c1a5cZ) Further company coverage: [ARRY.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Array Biopharma announces FDA acceptance of Binimetinib for patients with advanced NRAS-mutant melanoma
Thursday, 1 Sep 2016 08:00am EDT 

Array Biopharma Inc : Announces FDA acceptance Of Binimetinib NDA for patients with advanced NRAS mutant melanoma . Says currently preparing for an application orientation meeting (AOM) with FDA in September 2016 .FDA set target action date under prescription drug user fee act (PDUFA) of June 30, 2017.  Full Article

Array Biopharma files for mixed shelf of up to $300 mln
Thursday, 18 Aug 2016 05:24pm EDT 

Array Biopharma Inc :Files for mixed shelf of up to $300 million - SEC filing.  Full Article

Array Biopharma Q4 net loss $0.17 per share
Thursday, 4 Aug 2016 08:00am EDT 

Array Biopharma Inc : Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2016 . Net loss for Q4 was $0.17 per share . Revenue for Q4 of fiscal 2016 was $43.2 million, compared to $43.0 million for prior sequential quarter .Q4 earnings per share view $-0.14, revenue view $41.5 million -- Thomson Reuters I/B/E/S.  Full Article

Array Biopharma names new CFO
Thursday, 28 Jul 2016 08:00am EDT 

Array Biopharma Inc : Array Biopharma announces appointment of Jason Haddock as chief financial officer .Haddock's appointment effective today and he will be replacing David Horin, who had been acting as Array's interim CFO.  Full Article

More From Around the Web

BRIEF-Array BioPharma Q3 loss per share $0.21

* Array biopharma reports financial results for the third quarter of fiscal 2017